ZymoGenetics Claims Competitor's Product Poses Serious Patient Safety Issue
This article was originally published in The Pink Sheet Daily
As it tries to build market share for Recothrom, ZymoGenetics files Citizen's Petition asking FDA to remove its top competitor from the market.
You may also be interested in...
Agency takes issue with part of the better-than-bovine thrombin boast.
Company will price the recombinant, plasma-free thrombin at a 20 percent premium over competitor King's bovine-derived Thrombin JMI.
Bayer receives ex-U.S. rights to develop and market the recombinant thrombin therapy.